SecBot SecBot
8-K ·Filed Nov 5, 2026

ALNY

ALNYLAM PHARMACEUTICALS, INC.
NEUTRAL
Impact 4/10
Horizonweeks Processed11d 18h ago SEC0001178670-26-000080
8-K context-dependent: Items 5.02, 8.01
Actionable Insight • Neutral

The buyback is a capital return signal but non-binding; actual execution depends on market conditions and liquidity. Monitor the pace of repurchases in upcoming 10-Qs and whether the CCO departure leads to any commercial strategy changes.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$156.66
T+0 close · Nov 5, 2026 · via day close
Latest settled
−0.01%
T+5 · $156.65
Vs SPY
−3.30%
α at T+5
Next horizon
T+20
in 17d
  1. T+0 · Nov 5 $156.66entry
  2. T+1 · 11d ago −0.46%α −0.77% · $155.94
  3. T+5 · 5d ago −0.01%α −3.30% · $156.65
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alnylam announced the departure of Chief Commercialization Officer Tolga Tanguler in December 2026 and authorized a $1.0 billion share repurchase program, with $500 million expected by year-end 2026. The buyback signals capital return confidence, while the CCO departure is a routine executive change with no replacement named.

Key Facts

  • Tolga Tanguler, EVP and Chief Commercialization Officer, will depart in December 2026; no replacement named.
  • Board authorized a $1.0 billion share repurchase program on November 2, 2026.
  • Company anticipates repurchasing approximately $500 million by end of 2026 and the balance during 2027.
  • Repurchase program has no expiration date and may be modified, suspended or discontinued at any time.

Financial Impact

$1.0 billion buyback authorization, representing approximately 4.7% of $21.4B market cap; $500M expected by end of 2026.

share countcapital allocation

Risk Factors

  • Buyback may be modified, suspended or discontinued without notice; no obligation to repurchase any specific amount.
  • CCO departure without a named successor could create temporary leadership gap in commercialization.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
76% bullish (38 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001178670-26-000080
Document: 0001178670-26-000080-index-headers.html0001178670-26-000080
Document: 0001178670-26-000080-index.html0001178670-26-000080
Document: 0001178670-26-000080.txt0001178670-26-000080

Track record

15 reports on ALNY

Performance horizon

1 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +26.35% at T+5 after the Oct 23, 2026 report. 1 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $160.53 Now $159.73 −0.50% settles Nov 23
  2. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $165.50 Now $159.73 −3.49% settles Nov 23
  3. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $165.04 Now $159.73 −3.22% settles Nov 20
  4. Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $165.04 Now $159.73 −3.22% settles Nov 20
  5. Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $156.66 to $156.65 Now $159.73 +1.96% ▼ −0.01% −3.30% vs SPY
  6. Nov 5, 202611d ago 8-K Neutral 4/10 Viewing Entry $156.66 to $156.65 Now $159.73 +1.96% ▼ −0.01% −3.30% vs SPY
  7. Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $165.00 to $155.94 Now $159.73 −3.19% ▼ −5.49% −2.79% vs SPY
  8. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $174.00 to $156.66 Now $159.73 −8.20% ▼ −9.97% −5.24% vs SPY
  9. Oct 23, 202624d ago Institutional Cluster Bearish 4/10 Entry $224.03 to $165.00 Now $159.73 +28.70% ▲ +26.35% +25.79% vs SPY
  10. Aug 17, 202613w ago Court Ruling Neutral 4/10 Entry $228.61 to $240.08 Now $159.73 −30.13% ▲ +5.02% +5.22% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 7h 4m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026